BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33509905)

  • 41. Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-Snail signaling pathway.
    Yang Y; Zhang J; Zhu Y; Zhang Z; Sun H; Feng Y
    Int J Gynecol Cancer; 2014 Nov; 24(9):1564-74. PubMed ID: 25340291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
    Mehner C; Miller E; Hockla A; Coban M; Weroha SJ; Radisky DC; Radisky ES
    Oncogene; 2020 Oct; 39(42):6606-6618. PubMed ID: 32929152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
    Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
    Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines.
    Yoon H; Choi YL; Song JY; Do I; Kang SY; Ko YH; Song S; Kim BG
    PLoS One; 2014; 9(2):e88587. PubMed ID: 24523919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
    Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
    Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma.
    Marks EI; Brown VS; Dizon DS
    Am J Clin Oncol; 2020 Feb; 43(2):139-145. PubMed ID: 31764020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells.
    Miao F; Zhang X; Cao Y; Wang Y; Zhang X
    BMC Cancer; 2017 Dec; 17(1):838. PubMed ID: 29228922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Naturally occurring davanone terpenoid exhibits anticancer potential against ovarian cancer cells by inducing programmed cell death, by inducing caspase-dependent apoptosis, loss of mitochondrial membrane potential, inhibition of cell migration and invasion and targeting PI3K/AKT/MAPK signaling pathway.
    Cai J; Zhong YY; Tian S
    J BUON; 2020; 25(5):2301-2307. PubMed ID: 33277849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
    Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
    Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
    Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
    Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
    Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
    Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
    Li Y; Sun J; Gao S; Hu H; Xie P
    Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in
    Zundell JA; Fukumoto T; Lin J; Fatkhudinov N; Nacarelli T; Kossenkov AV; Liu Q; Cassel J; Hu CA; Wu S; Zhang R
    Cancer Res; 2021 Oct; 81(20):5325-5335. PubMed ID: 34548333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.
    Koshiyama M; Matsumura N; Baba T; Yamaguchi K; Yoshioka Y; Konishi I
    Cancer Biol Ther; 2014 Jan; 15(1):22-5. PubMed ID: 24096267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
    Kim M; Lu F; Zhang Y
    Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
    Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
    Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.